Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response

Published: 2025-06-01 10:47:08 ET RCUS

Published on 06/01/2025 at 10:47